Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-10-02 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Foreign Filer Report
2023-10-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a notification filed via RNS (London Stock Exchange news service) dated October 2, 2023. The content explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and provides the total number of voting rights (1,549,906,100) as of September 30, 2023. This type of filing, which reports on the total voting rights and capital structure for transparency purposes, fits best under the category related to voting rights and capital structure announcements. While it relates to voting rights, it is not the declaration of the *results* of a vote (DVA), but rather a routine regulatory update on the denominator used for shareholder notifications. Given the options, this is a specific regulatory announcement provided through the RNS system. Since there is no specific code for 'Voting Rights Update' and it is a mandatory regulatory disclosure, it falls under the general 'Regulatory Filings' (RNS) category, as it is a standard disclosure mechanism rather than a specific financial report or management change.
2023-10-02 English
DATO-DXD IMPROVED PFS IN BREAST CANCER
Foreign Filer Report
2023-09-25 English
Dato-DXd improved PFS in breast cancer
Earnings Release Classification · 1% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via RNS (Regulatory News Service). The content details positive Phase III trial results for a drug (datopotamab deruxtecan) and states that plans for global regulatory submissions are underway. It is a press release announcing clinical trial data, not a comprehensive financial report (like 10-K or IR) or a formal earnings release (ER). Since it is a general regulatory announcement that doesn't fit specific categories like DIV, MANG, or DIRS, the most appropriate classification is the general regulatory filing category, RNS. Q3 2023
2023-09-22 English
ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT
Foreign Filer Report
2023-09-20 English
Alexion completes Pfizer gene therapy agreement
M&A Activity Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a press release dated September 20, 2023, announcing a definitive purchase and license agreement between Alexion (AstraZeneca Rare Disease) and Pfizer regarding a gene therapy portfolio. This is a specific corporate action announcement, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). Since it is a formal announcement distributed via the RNS system, and it details a significant corporate transaction (M&A/licensing activity), it fits best under the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard announcements, or potentially M&A Activity (TAR). Given the structure and the explicit mention of 'RNS Number' and the RNS distribution service footer, RNS is the most appropriate classification for this type of regulatory news wire release that isn't covered by a more specific code like DIV or DIRS. The document length is short (3760 chars), suggesting it is an announcement rather than the full legal filing.
2023-09-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.